NeuroRx Secures Notice of Patent Allowance for PTSD Formulation

The U.S. Patent and Trademark Office has granted NeuroRx a patent for a post-traumatic stress disorder (PTSD) treatment.

The patent covers the combination of ketamine with the company's formulation of an antibiotic called D-cycloserine and an anti-depressant agent, the Radnor, Pa., drugmaker said. Ketamine is a short-acting anesthetic also used for the treatment of pain and depression.

According to the National Institutes of Health, PTSD affects 10 million to 13 million people in the U.S.